id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-312677-rwznqiib	Razmi, Mahdieh	Immunomodulatory-Based Therapy as a Potential Promising Treatment Strategy against Severe COVID-19 Patients: A Systematic Review	2020-08-29		.txt	text/plain	6545	306	39	Sixty-six publications and 111 clinical trials were recognized as eligible, reporting the efficacy of the immunomodulatory agents, including corticosteroids, hydroxychloroquine, passive and cytokine-targeted therapies, mesenchymal stem cells, and blood-purification therapy, in COVID-19 patients. Various studies have focused on the efficacy of the immunomodulatory agents including corticosteroids, hydroxychloroquine or chloroquine, cytokine-targeted therapies (e.g., anakinra, siltuximab, or tocilizumab), passive immunotherapy (convalescent plasma and intravenous immunoglobulin), mesenchymal stem cells, and bloodpurification therapy, mostly as adjuvant therapy for treatment of the patients with severe COVID-19 and partly have reported promising outcomes. Included clinical studies with 1-63 participants have shown that both antagonists, specially TCZ, are effective in reducing the mortality rate specially in the severely ill patients, improving the symptoms including fever resolution, oxygenation and resolved CT scans, reducing the inflammation markers (ferritin, CRP, and D-dimer), weaning from the ICU hospitalization and ventilation, and dampening the risk of disease progression to ARDS by mitigating the cytokine storm in the NCP patients [60, 62] , as applied for CRS controlling in the CAR-T therapy [90] .	./cache/cord-312677-rwznqiib.txt	./txt/cord-312677-rwznqiib.txt